

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/688,059	10/17/2003	Henry R. Costantino	1733.2025-004	8156
Elmore Craig, F	7590 06/12/2007:		EXAM	INER
209 Main Street No. Chelmsford, MA 01863			CORDERO GARCIA, MARCELA M	
No. Cheimstord	I, MA 01803		ART UNIT	PAPER NUMBER
			1654	
			MAIL DATE	DELIVERY MODE
			06/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

-,	Application No.	Applicant(s)			
,	10/688,059	COSTANTINO ET AL.			
Office Action Summary	Examiner	Art Unit			
	Marcela M. Cordero Garcia	1654			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
 Responsive to communication(s) filed on <u>09 March 2007</u>. This action is FINAL. 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i>, 1935 C.D. 11, 453 O.G. 213. 					
Disposition of Claims					
4) Claim(s) 1-19 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-19 are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some color None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s)	∧ □ Intercian 2	(DTO 412)			
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

DETAILED ACTION

Originally, a single claim (claim 1) was filed (October 17, 2003). The previous examiner of record issued a First Office Action dated July 17, 2006. New claims 2-19 were added on October 13, 2006. Final rejection (dated December 12, 2006) by the previous examiner of record examined PLGA [poly(lactide) co (glycolide)], sucrose and exendin-4 and necessitated a search commensurate in scope with the examination. Claims 18-19 were withdrawn in the Final rejection as not drawn to the elected invention (as originally presented). However, the claims are drawn not only to PLGA but also to poly(lactides), poly(glycolides), poly (lactic acid)s, poly(glycolic acid)s, poly(lactic acidco-glycolic acid)s and blends and copolymers thereof, which have different structures as the instantly examined polymer. In addition, the glucoregulatory peptides are drawn to, inter alia, GLP-1, GLP-2, exendin-3 and exendin-4 or combinations thereof, which are drawn to different biochemical and physical properties and chemical structures. In addition, the claims are drawn to sugars, including not only the previously examined sucrose, but also, e.g., trehalose, mannitol, and combinations thereof. Therefore, searching the full scope of the instant claims necessitates different searches depending on the polymers, peptides and sugars to be examined, and searching all the instant species claimed would be burdensome. Since the previous examiner of record does not appear to have examined all the inventions claimed in the application, it is deemed that searching all the product claims would indeed constitute a burdensome search. In order to clarify the record, the restriction requirement of December 12, 2006 is vacated and new grounds for restriction and election of species follow below.

Claims 1-19 are pending in the application.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- 1. Claims 1-17, drawn to a composition for sustained release of a biologically active polypeptide consisting essentially of: a biocompatible polymer having dispersed therein a biologically active glucoregulatory polypeptide. a sugar and glycine, classified, e.g., in class 514, subclass 2.
- II. Claims 18-19, drawn to a method of treating a patient suffering from Type 2 Diabetes, classified, e.g., in class 424, subclass 468.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case, the compositions for sustained release of a biologically active polypeptide may also be used, e.g., to study chemical stability of bioactive dispersions.

The search for each of the above inventions is not co-extensive particularly with regard to the literature search. Further, a reference which would anticipate the invention of one Group would not necessarily anticipate or even make obvious another Group.

Finally, the consideration for patentability is different in each case. Thus, it would be an undue burden to examine all of the above inventions in one application.

Because these inventions are distinct for the reasons given above and the search required for each Group is not necessarily required for the other Groups, restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement, to be complete, must include an election of the invention to be examined even though the requirement be traversed.

In addition, this application contains claims directed to the following patentably distinct species: the many and multiple biocompatible polylactide-co-glycolide polymers or biocompatible polymers (e.g., claim 15), the many and multiple biologically active glucoregulatory peptides (e.g., claim 2) and the many and multiple sugars (e.g., claims 10-13). The species are independent or distinct because they are drawn to distinct compositions having components with distinct chemical and physical properties.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species [i.e., elect a specific biocompatible polymer (e.g., claim 1 or 15), a specific glucoregulatory peptide (e.g., claim 2) and a specific sugar (e.g., claims 11-13)] for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 1-17 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, <u>and a listing of all claims</u>

readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions

unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).\

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Marcela M. Cordero Garcia whose telephone number is (571) 272-2939. The examiner can normally be reached on M-Th 7:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia J. Tsang can be reached on (571) 272-0562. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Marcela M Cordero Garcia

Page 6

Patent Examiner Art Unit 1654

MMCG 05/07